Plasma Concentrations of Risperidone and Olanzapine during Coadministration with Oxcarbazepine

Epilepsia

Volumn 46, Issue 5, 2005, Pages 771-774

  Muscatello, Maria Rosaria ^a   Pacetti, Monica ^a   Cacciola, Massimo ^a   La Torre, Diletta ^a   Zoccali, Rocco ^a   D'Arrigo, Concetta ^a   Migliardi, Gaetana ^a   Spina, Edoardo ^a,b  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

Author keywords

Drug interaction; Olanzapine; Oxcarbazepine; Risperidone

Indexed keywords

ANTICONVULSIVE AGENT; OLANZAPINE; OXCARBAZEPINE; PALIPERIDONE; RISPERIDONE;

ADJUVANT THERAPY; ADULT; ARTICLE; BIPOLAR DISORDER; CLINICAL ARTICLE; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG TOLERANCE; FATIGUE; FEMALE; HEADACHE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; PRIORITY JOURNAL; SCHIZOAFFECTIVE PSYCHOSIS; SEDATION; SIDE EFFECT; STEADY STATE;

ADULT; ANTICONVULSANTS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CARBAMAZEPINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; DRUG THERAPY, COMBINATION; EPILEPSY; FEMALE; HUMANS; MALE; MIDDLE AGED; RISPERIDONE;

EID: 18244384968     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2005.71104.x     Document Type: Article

References (15)

1. Spina E, Perucca E. Clinical significance of pharmacokinetic interactions between antiepileptic and psychotropic drugs. Epilepsia 2002;43(suppl 2):37-44.
2. th ed. Philadelphia: Lippincott Williams & Wilkins, 2002:476-8.
3. th ed. Philadelphia: Lippincott Williams & Wilkins, 2002:459-65.
4. th ed. Philadelphia: Lippincott Williams & Wilkins, 2002:247-61.
5. Fattore C, Cipolla G, Gatti G, et al. Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. Epilepsia 1999;40:783-7.
6. Zaccara G, Gangemi PF, Bendoni L, et al. Influence of single and repeated doses of oxcarbazepine on the pharmacokinetics profile of felodipine. Ther Drug Monit 1993;15:39-42.
7. Yasui-Furukori, Hidestrand M, Spina E, et al. Different enamioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes. Drug Metab Dispos 2001;29:1263-8.
8. Spina E, Scordo MG, D'Arrigo C. Metabolic drug interactions with new psychotropic agents. Fund Clin Pharmacol 2003;17:517-38.
9. Avenoso A, Facciolà G, Salemi M, et al. Determination of risperidone and its major metabolite 9-hydroxyrisperidone in human plasma by reversed-phase liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Appl 2000;746:173-81.
10. Boulton DW, Markowitz DS, DeVane CL. A high-performance liquid chromatography assay with ultraviolet detection for olanzapine in human plasma and urine. J Chromatol B Biomed Appl 2001;759:319-23.
11. th ed. Philadelphia: Lippincott Williams & Wilkins, 2002:465-9.
12. Spina E, Avenoso A, Facciolà G, et al. Plasma concentrations of risperidone and 9-hydroxyrisperidone: effect of comedication with carbamazepine or valproate. Ther Drug Monit 2000;22:481-5.
13. Linnet K, Olesen OV. Free and glucuronidated olanzapine serum concentrations in psychiatric patients: influence of carbamazepine comedication. Ther Drug Monit 2002;24:512-7.
14. Spina E, Scordo MG, Avenoso A, et al. Adverse drug interaction between risperidone and carbamazepine in a patient with chronic schizophrenia and deficient CYP2D6 activity. J Clin Psychopharmacol 2001;21:108-9.
15. Hedges D, Jeppson K, Whitehead P. Antipsychotic medication and seizures: a review. Drugs Today 2003;39:551-7.